Elephant's Foot: Deoxyelephantopin and the Cancer Research

This is the largest single body of research on Elephant's Foot, and it is genuinely substantial: dozens of papers from independent laboratories in Taiwan, mainland China, India, Malaysia and the United States, converging on the same active molecule and a coherent mechanism. It is also, without exception, cell culture and rodent work. No human trial of this plant, or of its lead compound deoxyelephantopin, for cancer of any kind, at any phase, exists. Both of those sentences are true at once, and a page that reports only one of them is not being honest with you.

Table of Contents

  1. The Short Version
  2. One Reactive Bond, Explained Once
  3. Cell-Line Evidence Across Cancer Types
  4. From Dish to Animal: What the Mouse Data Shows
  5. The Sorafenib Comparison, and Why "Beat the Drug" Claims Need a Caveat
  6. Working Alongside Chemotherapy Drugs
  7. A Suppressive Effect That Cuts Both Ways
  8. Why the Cell-to-Clinic Gap Is Enormous
  9. If You or Someone You Love Has Cancer
  10. Key Research Papers
  11. Connections

The Short Version

Deoxyelephantopin and its isomer isodeoxyelephantopin — germacrane-type sesquiterpene lactones concentrated in Elephantopus scaber — kill cancer cells in culture across an unusually wide range of tissue types, and they slow tumor growth in several mouse models. The work spans nasopharyngeal, lung, colorectal, cervical, hepatocellular, pancreatic, breast, bladder, brain, bone, oral and kidney cancer cell lines, plus melanoma and, in one study, uterine fibroid (leiomyoma) tissue. Four independent research groups — a Taiwan Academia Sinica group led by Lie-Fen Shyur, a UNC/Kanazawa medicinal-chemistry program led by Kuo-Hsiung Lee and Kyoko Nakagawa-Goto, a Shenyang Pharmaceutical University group isolating and testing new sesquiterpene lactones from the plant, and several Indian and Chinese hospital-affiliated labs — have converged on the same compound and a shared, mechanistically coherent story. That degree of independent replication is unusual for a traditional-medicine plant and is the reason this page treats the preclinical work seriously rather than dismissing it.

Set against that: zero human trials. Not phase I, not a single case series, not even a published human pharmacokinetic study establishing what happens to deoxyelephantopin after it is swallowed. The word "human" appears throughout this literature — but overwhelmingly to describe the cell line ("human colorectal carcinoma cells," "human lymphocyte proliferation," "human ether-a-go-go-related gene expression"), not a person in a clinic. That distinction matters enough that it is worth stating plainly before anything else on this page: a human cancer cell line growing in a dish is not a human being with cancer.

Back to Table of Contents

One Reactive Bond, Explained Once

The main Elephant's Foot page explains this mechanism in full; the short version here is enough to follow the rest of this article. Deoxyelephantopin and its relatives carry an α-methylene-γ-butyrolactone group — a strained, electron-poor double bond next to a carbonyl that acts as a Michael acceptor. It reacts irreversibly with the thiol (-SH) group of cysteine, the most abundant soft nucleophile in a cell. Two cysteine targets explain most of the anticancer literature below: a critical cysteine on IKKβ, whose alkylation shuts down the NF-κB survival pathway that many tumors depend on, and the cell's glutathione pool, whose depletion raises oxidative stress selectively in cells that already run with less redox reserve — a description that fits many cancer cells. Newer work adds specific protein targets to this list: thioredoxin reductase 1, a second redox-defense enzyme, and the chaperone protein Hsp90α, both identified as direct deoxyelephantopin-binding partners in more recent studies.

This is a promiscuous mechanism by design — the molecule reacts with any sufficiently exposed cysteine, not one dedicated receptor — and that promiscuity is the double-edged property that runs through this entire page.

Back to Table of Contents

Cell-Line Evidence Across Cancer Types

What follows is not an exhaustive list but is representative of the range. In every case, the finding is that deoxyelephantopin, isodeoxyelephantopin, or a related sesquiterpene lactone from this plant induces apoptosis (programmed cell death) or arrests the cell cycle in a human cancer cell line, generally at low micromolar concentrations.

A 2020 Indonesian study took a different approach, testing whole ethanol extract (not isolated deoxyelephantopin) against DMBA — a carcinogen that also damages the liver and kidneys as it is metabolized — in rats, and reported anticancer, hepatoprotective and nephroprotective activity from the same extract in the same animals. One further data point complicates a purely celebratory reading: a 2012 study found that sesquiterpene lactones isolated from this plant inhibited human lymphocyte proliferation in vitro at the same time as they killed tumor cell lines and induced apoptosis — the compound does not distinguish a malignant cell from a healthy immune cell asked to proliferate. That finding is developed further below.

Back to Table of Contents

From Dish to Animal: What the Mouse Data Shows

Cell-culture results are the easiest data to generate and the least predictive of what happens in a whole organism, so the mouse studies matter more than their smaller number suggests:

This is real in vivo evidence, not merely cell culture, and it is worth saying so plainly. It is also still four mouse studies, in specific inbred strains, at researcher-chosen doses and routes, for specific cancer types — not a demonstrated human treatment.

Back to Table of Contents

The Sorafenib Comparison, and Why "Beat the Drug" Claims Need a Caveat

The hepatocellular carcinoma paper above found that deoxyelephantopin was more potent than sorafenib against HepG2 and Hep3B cells in a concentration-dependent manner. Sorafenib is a real, FDA-approved drug for advanced liver cancer, so on its face this sounds like a striking result. It needs a specific caveat that applies to any "beat the approved drug" claim from a cell-culture study: sorafenib's own benefit in liver cancer, established in real clinical trials, is genuine but modest — it extends survival by a period best measured in months, not years, in advanced disease. A compound that outperforms a modestly effective drug in a petri dish has cleared a real but low bar. It says nothing about whether deoxyelephantopin would survive first-pass liver metabolism, reach tumor tissue at an effective concentration, or avoid the toxicity that sorafenib itself carries (it is not a benign drug; it has its own list of serious side effects). The comparison is scientifically useful — it is a reasonable way to rank candidate compounds inside a screening program — and it is not evidence that deoxyelephantopin works better than sorafenib in a person, because that comparison has never been run.

Back to Table of Contents

Working Alongside Chemotherapy Drugs

The most scientifically interesting thread in this literature is not "deoxyelephantopin instead of chemotherapy" but deoxyelephantopin alongside it — several papers report that it increases cancer cells' sensitivity to drugs already used in the clinic:

This pattern — a plant compound that potentiates an existing, approved drug rather than replacing it — is scientifically the most promising angle in this entire literature, because chemoresistance is one of oncology's hardest unsolved problems and any real chemosensitizer would matter. It is also the angle most likely to be misread as an invitation to self-combine. None of this is evidence that taking an Elephant's Foot supplement alongside your prescribed chemotherapy is safe or helpful. Every one of these results used isolated, purified compound at a researcher-controlled dose, not whole-plant extract of unknown potency, and none has been tested in a human being receiving actual chemotherapy. An unstudied combination is not automatically dangerous, but it is not automatically safe either, and "not yet studied" is the honest description of where this stands.

Back to Table of Contents

A Suppressive Effect That Cuts Both Ways

Two findings in this literature point at the same uncomfortable fact from different directions. The 2012 lymphocyte study noted above found that sesquiterpene lactones from this plant suppressed proliferation of normal human lymphocytes at the same concentrations that killed tumor cells. A 2026 paper went further and named the mechanism precisely: deoxyelephantopin suppressed interleukin-2 (IL-2) production in activated T lymphocytes by inhibiting both NF-κB and the calcineurin/NFAT signaling pathway.

Calcineurin/NFAT is not an obscure pathway. It is the specific mechanism of ciclosporin and tacrolimus, the calcineurin-inhibitor drugs used to prevent transplant rejection and to treat severe autoimmune disease precisely because they suppress T-cell activation. A compound shown to inhibit the same pathway is, mechanistically, doing something similar. That is not automatically a reason for alarm at traditional decoction doses, and it is a real reason for two specific groups of people to be cautious with concentrated preparations: anyone with active cancer, whose own immune system is one of the tools working against the tumor (and who may be a candidate for immunotherapy, an entire drug class that works by releasing immune suppression rather than adding to it), and anyone taking an actual calcineurin inhibitor or other immunosuppressant, for whom an additive, unstudied effect is a plausible risk rather than a theoretical one.

Back to Table of Contents

Why the Cell-to-Clinic Gap Is Enormous

Most candidate anticancer compounds that ever reach a human trial — already having survived years of preclinical filtering — fail to reach approval, and oncology has the worst attrition rate of any therapeutic area in drug development. Deoxyelephantopin has not yet entered that pipeline at all; it sits at a considerably earlier and less-filtered stage than a compound that has already failed a phase II trial. Several specific gaps explain why:

Back to Table of Contents

If You or Someone You Love Has Cancer

This is the section that matters most, so it is stated directly rather than folded into a caution list at the bottom of the page. Do not substitute this plant, or any preparation of it, for medical cancer treatment. The reasons are concrete:

If you are in active treatment and want to try a plant-derived product, the useful step is telling your oncology team what you are taking, not researching around them. They cannot account for an interaction they do not know about.

Back to Table of Contents

Key Research Papers

Every citation below is a PubMed search link, not a numeric identifier — each was checked to confirm it returns the intended record before being written into this page. Author names, titles and journals are given as plain text so you can verify them independently.

  1. Su M, Chung HY, Li Y, et al. Deoxyelephantopin from Elephantopus scaber L. induces cell-cycle arrest and apoptosis in the human nasopharyngeal cancer CNE cells (2011). Biochemical and Biophysical Research Communications. — Find on PubMed
  2. Kabeer FA, Sreedevi GB, Nair MS, et al. Antineoplastic effects of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber, on lung adenocarcinoma (A549) cells (2013). Journal of Integrative Medicine. — Find on PubMed
  3. Chan CK, Supriady H, Goh BH, et al. Elephantopus scaber induces apoptosis through ROS-dependent mitochondrial signaling pathway in HCT116 human colorectal carcinoma cells (2015). Journal of Ethnopharmacology. — Find on PubMed
  4. Chen JJ, Yan QL, Bai M, et al. Deoxyelephantopin, a germacrane-type sesquiterpene lactone from Elephantopus scaber, induces mitochondrial apoptosis of hepatocarcinoma cells by targeting Hsp90α in vitro and in vivo (2023). Phytotherapy Research. — Find on PubMed. The sorafenib-comparison and xenograft study discussed above.
  5. Cvetanova B, Li MY, Yang CC, et al. Sesquiterpene Lactone Deoxyelephantopin Isolated from Elephantopus scaber and Its Derivative DETD-35 Suppress BRAF(V600E) Mutant Melanoma Lung Metastasis in Mice (2021). International Journal of Molecular Sciences. — Find on PubMed
  6. Ji D, Zhong X, Huang P, et al. Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity in vitro and in vivo through targeting the NF-κB signaling pathway in pancreatic cancer (2020). Aging. — Find on PubMed
  7. Duan D, Wang Y, Pan D, et al. Targeting thioredoxin reductase by deoxyelephantopin from Elephantopus scaber triggers cancer cell apoptosis (2021). Archives of Biochemistry and Biophysics. — Find on PubMed
  8. Geetha BS, Nair MS, Latha PG, et al. Sesquiterpene lactones isolated from Elephantopus scaber L. inhibits human lymphocyte proliferation and the growth of tumour cell lines and induces apoptosis in vitro (2012). Journal of Biomedicine and Biotechnology. — Find on PubMed. The lymphocyte-suppression finding discussed above.
  9. Sulistyani N, Nurkhasanah. Screening of anticancer, hepatoprotective and nephroprotective effects of ethanol extract of Elephantopus scaber L. (2020). Pakistan Journal of Pharmaceutical Sciences. — Find on PubMed. The DMBA rat model discussed above.
  10. Cai M, Qi R, Wang M, et al. Deoxyelephantopin, a natural sesquiterpene lactone, suppresses IL-2 production of ConA-activated T lymphocytes through inhibiting NF-κB and calcineurin/NFAT signaling (2026). European Journal of Pharmacology. — Find on PubMed. The calcineurin/NFAT immune-suppression finding discussed above.
  11. Priyadarshni A, Sharma R, Bora KS, Dewangan HK. Pharmacological insights into deoxyelephantopin: a multifunctional sesquiterpene with therapeutic promise in cancer and neurodegenerative disorders (2026). Molecular Biology Reports. — Find on PubMed. Recent review; useful for the full breadth of cell lines tested.
  12. Pandey V, Tripathi A, Rani A, et al. Deoxyelephantopin, a novel naturally occurring phytochemical impairs growth, induces G2/M arrest, ROS-mediated apoptosis and modulates lncRNA expression against uterine leiomyoma (2020). Biomedicine & Pharmacotherapy. — Find on PubMed
  13. Johnson SB, Park HS, Gross CP, Yu JB. Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers (2018). JAMA Oncology / related Journal of the National Cancer Institute work by the same group. — Find on PubMed. The alternative-medicine-and-survival evidence cited above; verify the exact venue yourself, as this group published closely related findings in more than one journal.

Live PubMed Searches

Back to Table of Contents

Connections

Back to Table of Contents